亞盛醫藥(06855.HK)擬配售1500萬股新股份 融資約7.02億港元
格隆匯 7 月 8日丨亞盛醫藥－Ｂ(06855.HK)發佈公告，2020年7月8日，公司與配售代理(Citigroup Global Markets Limited及摩根大通證券(亞太)有限公司)訂立配售協議，據此，配售代理同意(個別而非共同或共同及個別)作為公司的代理，在配售協議的條款及條件規限下，按盡力基準促使承配人按配售價每股配售股份46.80港元認購合共1500萬股配售股份。
配售股份數目相當於公司現有已發行股本約7.18%及公司經擴大已發行股本約6.70%。配售股份將根據一般授權發行，配發及發行配售股份無需獲得額外股東批准。公司將向聯交所申請批准配售股份上市及買賣。
假設全部1500萬股配售股份獲悉數認購，配售事項將籌集的所得款項總額將約為7.02億港元，而配售事項產生的所得款項淨額估計約為6.895億港元。按此基準，每股配售股份的淨價將約為45.96港元。
集團為一間放眼全球的臨牀階段生物科技公司，從事開發治療癌症、乙型肝炎病毒(HBV)及衰老相關疾病的新型療法。董事認為，配售事項為公司籌集資金的良機，同時可擴大其股東基礎。配售事項將鞏固集團的財務狀況，併為集團提供營運資金。
配售所得款項淨額將用於(i)公司已於2020年6月提交新藥申請(NDA)的核心產品HQP1351(第三代BCR-ABL/KIT多激酶抑制劑)的註冊、試產及營銷；(ii)其他在研產品的臨牀開發，如APG-2575(目前處於Ib/II期臨牀試驗的Bcl-2選擇性抑制劑)、APG-115(目前處於Ib/II期臨牀試驗的MDM2–p53抑制劑)、APG-1387(目前處於Ib/II期臨牀試驗的泛IAP抑制劑)及APG-1252(目前處於I期臨牀試驗的Bcl-2/Bcl-xL雙重抑制劑)；及(iii)一般企業用途(如適用)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
